Richard Schraeder, MD
Hematology & Oncology · Towson, MDNPI 1285775239
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,932 of the $2,222 with a category attached, or 87.0%. It is spread thinly across 30 manufacturers, the largest accounting for just 9.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $722 and has fallen 83.2% since, to $121 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MD, where the typical reported total is $2,111.
Across 93 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$206
- Seagen Inc.$202
- EMD Serono, Inc.$149
- Johnson & Johnson$147
- GSK$138
- Incyte Corporation$136
- plus $1K from 24 others
Across 12 payments — averaging $1620.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Puma Biotechnology, Inc.$19K
- Merck$127
What the payments were for
- Food & beverage$1,93287%
- Education$28913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $206 |
| Seagen Inc. | 10 | $202 |
| EMD Serono, Inc. | 8 | $149 |
| Johnson & Johnson | 6 | $147 |
| GSK | 5 | $138 |
| Incyte Corporation | 3 | $136 |
| Lilly USA, LLC | 2 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $118 |
| AstraZeneca(2 entities) | 5 | $115 |
| Pfizer | 6 | $113 |
| Bristol Myers Squibb | 3 | $89 |
| Boehringer Ingelheim | 4 | $86 |
| Genentech USA, Inc. | 4 | $80 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Novartis | 2 | $45 |
| Tempus AI, Inc | 2 | $43 |
| Astellas Pharma US Inc | 2 | $43 |
| Gilead(2 entities) | 3 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Beigene USA, Inc. | 1 | $34 |
| Amgen | 2 | $34 |
| Merck | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $26 |
| Tolmar, Inc. | 1 | $25 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Array Biopharma Inc | 1 | $23 |
| Dova Pharmaceuticals | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $16 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
How this compares
$2,222 in reported general payments places this provider in the 50th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 16 | $305,148 |
| BrukinsaZanubrutinib | 14 | $191,826 |
| PromactaEltrombopag Olamine | 12 | $88,695 |
| EliquisApixaban | 20 | $15,939 |
| Hydroxyurea | 34 | $923 |
| Acyclovir | 22 | $414 |
| Anastrozole | 11 | $317 |
| Prochlorperazine Maleate | 24 | $297 |
| Dexamethasone | 27 | $274 |
| Ondansetron Hcl | 28 | $214 |
| Allopurinol | 19 | $91 |
| Prednisone | 14 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $43 | $305,14816 claims |
| Beigene USA, Inc.Brukinsa | $34 | $191,82614 claims |
| NovartisPromacta | $45 | $88,69512 claims |
| PfizerEliquis | $113 | $15,93920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Towson
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
- Walid El AyassSalisbury$111K
- Arun BhandariAnnapolis$103K
- Huzefa BahrainBaltimore$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.